Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients by Paola Parrella et al.
Parrella et al. Molecular Cancer 2014, 13:142
http://www.molecular-cancer.com/content/13/1/142RESEARCH Open AccessEvaluation of microRNA-10b prognostic
significance in a prospective cohort of breast
cancer patients
Paola Parrella1*†, Raffaela Barbano1†, Barbara Pasculli2, Andrea Fontana3, Massimiliano Copetti3, Vanna Maria Valori4,
Maria Luana Poeta1, Giuseppe Perrone5, Daniela Righi5, Marina Castelvetere6, Michelina Coco1, Teresa Balsamo1,
Maria Morritti4, Fabio Pellegrini2,7, Andrea Onetti-Muda5, Evaristo Maiello4, Roberto Murgo8 and Vito Michele Fazio1,9Abstract
Background: MicroRNA-10b (miR-10b) has a prominent role in regulating tumor invasion and metastasis by
targeting the HOXD10 transcriptional repressor and has been found up-regulated in several tumor types.
Methods: We evaluated the expression of miR-10b in paired tumor and normal specimens obtained from a
prospective cohort of breast cancer patients with at least 36 months follow-up enrolled according to the REMARK
guidelines (n = 150). RNA quality was measured and only samples with RNA Integrity Number (RIN) ≥7.0 were
analyzed.
Results: The relative expression of miR-10b in tumor as compared to its normal counterpart (RER) was determined
by RT-qPCR. miR-10b RERs were higher in the subgroup of patients with synchronous metastases (n = 11, Median
0.25; IQR 0.11-1.02) as compared with patients without metastases (n = 90, Median 0.09; IQR 0.04-0.29) (p = 0.028).
In the subgroup of patients without synchronous metastases (n = 90), higher miR-10b RERs were associated with
increased risk of disease progression and death in both univariable (HR 1.16, p = 0.021 and HR 1.20, p = 0.015
respectively for 0.10 unitary increase of miR-10b RERs levels) and multivariable (HR1.30, p < 0.001, and HR 1.31,
p = 0.003 respectively for 0.10 unitary increase of miR-10b RERs levels) Cox regression models. The addition of
miR-10b RERs to the Nottingham Prognostic Index (NPI) provided an improvement in discrimination power and
risk reclassification abilities for the clinical outcomes at 36 months. Survival C-indices significantly increased from
0.849 to 0.889 (p = 0.009) for OS and from 0.735 to 0.767 (p = 0.050) for DFS.
Conclusions: Our results provide evidences that the addition of miR-10b RERs to the prognostic factors used in
clinical routine could improve the prediction abilities for both overall mortality and disease progression in breast
cancer patients.
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In recent years mortality from breast cancer has declined
in western countries likely as a result of more widespread
screening resulting in earlier detection, as well as advances
in the adjuvant treatment [1]. Several prognostic factors
are currently used in routine practice to select patients* Correspondence: pparrella@operapadrepio.it
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unless otherwise stated.most likely to recur without adjuvant therapy and there-
fore that potentially benefit from therapy. However, even
patients with better prognosis may develop metastases
and die for the disease [2]. Recent studies have shown that
the metastatic capability of cancer is conferred by molecu-
lar changes arising relatively early in tumorigenesis and
metastatic dissemination may occur continually through-
out the course of primary tumor development [3].
MicroRNAs (miRNAs) are small cellular RNAs modu-
lating gene expression at post-transcriptional level [4].
miR-10b was initially found highly expressed in metastaticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological characteristics of the patients
cohort (n = 101)
Characteristics n %
Tumor histotype Ductal 92 91.1
Lobular 7 6.9
Others 2 2.0








Metastases Absent 90 89.1
Present 11 10.9




ER status Negative 38 37.6
Positive 63 62.4
PgR status Negative 50 49.5
Positive 51 50.5
HER2 amplification Negative 66 65.3
Positive 30 29.7
Missing 5 5.0
Receptor Classification Receptor positive 63 62.4
Triple Negative 20 19.8
Her2/neu amplified 18 17.8









NPI Low Risk 16 18.0
Intermediate Risk 43 48.3
High Risk 30 33.7
Adjuvant therapy* HT + CT 53 58.9
CT 18 20.0
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growing as primary tumor in mice [5]. Moreover, miR-10b
silencing by antagomirs markedly suppresses metastases
formation in the 4 T1 mouse model although has no
effects on tumor growth [6]. The mechanisms by which
miR-10b is involved in metastatic processes have been
extensively studied in breast cancer cell lines as well as
in cells derived by other tumor types [7]. miR-10b has a
prominent role in regulating tumor invasion and metas-
tasis by targeting the HOXD10, a transcriptional repres-
sor involved in cellular migration and extracellular
modelling such as RhoC, uPAR, α3-integrin and MT1-
MMP [5,7-12].
In their original study, Ma and colleagues [5] evaluated
miR-10b expression relative to normal mammary tissue
in 23 advanced stage breast cancers, finding higher
miR-10b levels in metastatic tumors as compared with
non-metastatic cancers. A correlation between elevated
miR-10b expression and poor prognosis was recently
reported in gastric cancer, renal cancer, colorectal tu-
mors, pancreatic cancer and bladder tumors [11,13-19].
Moreover, higher miR-10b expression levels were re-
cently detected in serum from metastatic breast cancer
patients [20].
To further clarify the role of miR-10b as prognostic
biomarker in breast cancer, we evaluated the association
between miR-10b expression and clinical outcome in a
cohort of prospectively collected breast cancer tissues.
Results
Patients and treatment
Table 1 summarizes descriptive statistics for the 101
cases selected for our analysis. The median age of the
study population is 59 years (range, 36 to 82), median
tumor size is 2.5 cm (range, 1.0 to 10.0). Metastases at
diagnosis (synchronous metastases) were present in 11
cases whereas, among non-metastatic patients, 34 expe-
rienced disease progression and 30 of them developed
distant metastases (metachronous metastases).
All patients received adequate local treatment (breast
conserving surgery or total mastectomy) plus sentinel
node biopsy or complete axillary dissection. Post-surgery
treatments were performed according to the following
guidelines: San Gallen, NCCN and ASCO. Adjuvant
therapy in association with postoperative breast irradi-
ation (RT) was performed in 89 patients because one
subject refused treatment.
Evaluation of miR-10b expression in breast tissues by
RT-qPCR
miR-10b expression was evaluated in paired normal and
tumor tissues obtained from 101 patients. As expected
from previous studies [7,21-23] overall miR-10b expres-
sion levels (miR-10b/RNU48x1000) were lower in tumor
Table 1 Clinicopathological characteristics of the patients
cohort (n = 101) (Continued)
Ct + anti-HER2 16 17.8
HT 2 2.2
None 1 1.1
*HT, Hormone Therapy; CT, Chemotherapy.
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values of 28.33 (IQR 10.68-62.71) and 254.95 (IQR
110.28-495.09). Thus, to determine tumor specific
changes we evaluated for each patient the ratio between
the levels of miR-10b expression in cancer specimen to
the levels of miR-10b expression in paired normal tissue
(RER). RERs ranged from 0.05 to 1.7 with a median
value of 0.10 (IQR 0.05-0.32).Association of miR-10b RERs with distant metastases
The only significant association with clinicopathological
characteristics was found between miR-10b RERs and the
presence of distant metastases at diagnosis (Additional
file 1: Table S1). miR-10b RERs were significantly higher
in the subgroup of patients with metastases (Median
0.25; IQR 0.11-1.02) as compared with patients without
metastases (Median 0.09; IQR 0.04-0.29) (p = 0.028). No
statistically significant difference was found in miR-10b
RERs between patients with synchronous (N = 11) and
metachronous metastasis (N = 30) (t-test p = 0.096).Figure 1 HOXD10 protein expression by immunohistochemistry. a) re
individual (HBS1): HOXD10 was constitutively expressed in normal ductal a
control. b) representative image of breast cancer case BC4 developing dist
0.78 and HOXD10 protein was expressed in 20% of cancer cells; c) and d) r
cases. HOXD10 showed a diffuse staining, miR-10b RERs were 0.01 and 0.42
respectively. Original magnification: 100X a, b, c, d images; 400X squared aIn the 41 patients with synchronous or metachronous
distant metastases, the group of patients with brain metas-
tases (n = 6) had significantly higher miR-10b RERs (Median
0.47; IQR 0.20-1.62) as compared with patients (n = 35)
showing metastases in other organ sites (Median 0.10; IQR
0.03-0.61) (t-test p = 0.043) (Additional file 1: Table S1).
HOXD10 protein expression is inversely correlated with
miR-10b expression levels in breast tissues
We evaluated by IHC the expression of miR-10b target
gene HOXD10 in three normal breast tissues from
reductive mammoplasty and 10 paired normal and
tumor tissues (Additional file 1: Table S1). HOXD10 was
constitutively expressed in normal ductal and lobular
epithelium (Figure 1a). In tumor tissues HOXD10 was
variably expressed with tumors showing a diffuse immu-
nostaining (Figure 1c-d) and tumors with a low percent-
age of stained cancer cells (Figure 1b). A statistically
significant inverse correlation was found among miR-10b
expression levels and percentage of HOXD10 expressing
cells (Spearman Rho −0.713 p < 0.001).
Association of miR-10b RERs with survival in patients
without synchronous metastases
The association with survival was evaluated by using miR-
10b RERs values as a continuous variable in the group of
patients without metastases at diagnosis (n = 90). In uni-
variable Cox regression model, patients with higher miR-
10b RERs showed an increased risk of disease progressionpresentative image of normal breast epithelium from an healthy
nd lobular epithelium and therefore were used as internal positive
ant metastases (brain, bone, liver) during follow-up: miR-10b RERs were
epresentative images of BC6 and BC7 non-metastatic breast cancer
respectively and percentage of stained cells were 70% and 100%
rea of an image.
Table 2 Proportional hazards Cox regression models evaluating the association between miR-10b RERs and Overall
Survival (OS), Disease Free Survival (DFS) and Metastases Free Survival (MFS) in the 90 cases without metastases at
diagnosis
Outcome Median follow-up (range)* Events/Total Model HR 95% CI p
Disease Free Survival (DFS) 39.88 (21.17 – 58.77) 34/90 Univariable 1.16 1.02-1.31 0.021
31/79 Multivariable 1.30 1.11-1.51 <0.001
Metastasis-Free Survival (MFS) 43.57 (25.23 – 59.77) 30/90 Univariable 1.17 1.03-1.34 0.019
27/79 Multivariable 1.34 1.13-1.59 <0.001
Overall Survival (OS) 45.78 (32.60 – 60.50) 18/90 Univariable 1.20 1.04-1.38 0.015
16/79 Multivariable 1.31 1.10-1.57 0.003
Abbreviations: HR Hazard Ratio, 95% CI, 95% Confidence Interval.
Multivariable models included: T, N, Grade, ER, PgR, HER2 and KI67.
HR were reported for each unitary increase of 0.1 miR-10b RERs.
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p = 0.019), and cancer related death (HR1.20; p = 0.015)
(Table 2). Other factors associated with outcome in
univariable analysis are shown in Additional file 1: Table
S2. A multivariable Cox regression model adjusted for
tumor size, lymph node metastases, Grade, ER and PgR
status, and KI67 labeling index (n = 79), confirmed that
increased miR-10b RERs were associated with higher
risk of disease progression (HR1.30; p < 0.001), distant
metastases (HR1.34; p < 0.001) and worse overall survival
(HR1.31; p = 0.003) (Table 2). The assumption of pro-
portional hazards was satisfied.
Association of miR-10b RERs with response to adjuvant
treatment
The association of miR-10b RERs with response to ther-
apy in terms of DFS and MFS was also evaluated. In uni-
variable Cox regression analysis, a statistically significant
association between higher RERs and risk of metastases
development was found in the subgroup of patients
treated with hormone therapy in association with
chemotherapy (HR1.22, p = 0.039). A trend toward an
association was found for the same subgroup with DFS
(HR1.18, p = 0.063) (Additional file 1: Table S3).Table 3 Measures of model performance of Nottingham Prog
A) Overall survival
Model Calibration (p-value) Survival C-index (95% CI)
NPI 0.999 0.849 (0.78-0.92)
NPI+miR-10b RERs 0.999 0.889 (0.82-0.96)
B) Disease free survival
NPI 0.999 0.735 (0.656-0.815)
NPI+miR-10b RERs 0.942 0.767 (0.676-0.859)Performance of NPI and NPI +miR-10b RERs in predicting
short term outcome in the patient population
We evaluated whether the addition of miR-10b RERs to
the model with NPI index alone was able to provide im-
provements in discriminatory power and risk reclassifi-
cation abilities for the clinical outcomes at 36 months.
As shown in Table 3, the survival C-indices significantly
increased from 0.849 to 0.889 (p = 0.009) for OS and
from 0.735 to 0.767 (p = 0.050) for DFS with the inclu-
sion of miR-10b RERs, along with a very good calibra-
tion (all HL p-values were greater than 0.94) for the OS
and DFS outcomes, respectively. Furthermore, the
addition of miR-10b RERs to the NPI for OS allowed to
correctly reclassify 31 out of 89 patients, where 1 of 11
were events (10.4%) and 30 of 70 were non-events
(43.4%), providing a cNRI of 0.538 (p = 0.061).
The addition of miR-10b RERs to the NPI for DFS
allowed to correctly reclassify 29 out of 89 patients
where: only 30 of 56 non-events (53.8%) were correctly
reclassified while 1 of 25 events (4.2%) was misclassified,
providing therefore a cNRI of 0.496 (p = 0.015). There-
fore, a large proportion of non-events were correctly re-
classified when considering both NPI and miR-10b RERs
into the prediction models for both clinical outcomes.nostic Index (NPI), without and without miR-10b RERs
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MicroRNA-10b was identified as a miRNA highly
expressed in metastatic breast cancer cell lines, able to
generate metastases when growing as primary mammary
tumor in mice [5,6]. Although Gee and colleagues [21]
did not find association between miR-10b and outcome
in a retrospective breast cancer cohort, an association
between elevated miR-10b expression and poor progno-
sis was reported in several tumor types [11,13-19]. Thus,
we took the effort to further evaluate the putative role of
miR-10b as prognostic biomarker in breast cancer by
analyzing a cohort of prospective collected cases with at
least 3 years follow-up from our tumor bank.
To overcome the variability of miR-10b expression in
normal breast tissues and tumor samples [7,21-23], we
developed a reliable RT-qPCR approach for the detec-
tion of changes directly linked to cancer phenotype. Al-
though cancer samples can be enriched of tumor cells
by performing laser microdissection, recent studies sug-
gest that tumor microenvironment plays a pivotal role in
maintaining malignant phenotypes [24]. Therefore the
analysis of whole tumor tissues is likely to be more in-
formative and accurate than the analysis of isolated epi-
thelial component. The goodness of our analytical
approach is further sustained by the inverse correlation
found in tissues between miR-10b levels determined by
RT-qPCR and the expression of miR-10b target
HOXD10 by immunostaining. This result is more re-
markable considering that miR-10b expression analysis
and HOXD10 immunostaining were performed on two
independent samples.
We show that although miR-10b is overall down regu-
lated in tumors with a median RER value of 0.10, meta-
static breast cancers show significantly higher RERs
(median 0.25) than non-metastatic tumors (median
0.09), thus confirming the initial data by Ma and col-
leagues [5]. Interestingly, a recent study reported in-
creased miR-10b expression in serum obtained from
breast cancer patients with higher levels in metastatic
tumors as compared with non-metastatic cancers (20).
Moreover, Chan and colleagues [25] demonstrated that
while miR-10b is down regulated in tumor tissues as
compared to normal breast, it shows overexpression in
corresponding serum specimens. These data are consist-
ent with our results and might be explained by the exist-
ence of a miR-10b over-expressing subpopulation within
primary tumor responsible of miR-10b shed in the
bloodstream. We can speculate that the more this miR-
10b overexpressing subpopulation is represented in
primary tumor the higher is the risk for the patient to
develop distant metastases.
In our cohort, patients showing higher miR-10b RER
were more likely to progress, develop metastases and die
for the disease. These associations are independent fromthe prognostic factors used in routine practice to stratify
patients according to their risk to progress. Our results
also suggest that high miR-10b RERs might be involved
in primary resistance to hormone therapy, although
these data are limited by the small sample size of therap-
ies subgroups.
A limitation of our study is the scarce representation
in the population of cases classified at low risk by the
NPI. This is mainly due to the restrictions for tumor
banking which allow only the collection of tumor greater
than 1.0 cm in diameter, thus affecting one of the main
factors included in the NPI. Nevertheless, we found that
the addition of miR-10b RERs to the NPI for the predic-
tion of both overall mortality and disease progression
risks in breast cancer patients significantly increased the
model’s discriminatory power and the risk reclassifica-
tions within 36 months of follow up.
Conclusions
This study provides evidences that miR-10b expression
is associated with clinical outcome in breast cancer pa-
tients. If these results will be confirmed on a longer
follow-up, miR-10b RERs could be used as biomarkers
for a better patient’s risk stratification. Lower miR-10b
RERs identify those breast cancer patients who despite
having clinical features associated with adverse outcome
might not need intensive adjuvant treatment. Moreover
for those patients with higher miR-10b RERs, the identi-
fication of agents able to specifically silence miR-10b in
cancer cell or modulate its downstream effectors may




This study is part of a single institution project initiated in
2006, aimed to the identification of novel biomarkers pre-
dicting disease progression and metastases development in
breast cancer patients. The study is conducted according to
the REporting of tumor MARKer Studies (REMARK)
guideline [26] and a prospectively written research, patho-
logic evaluation, and statistical analysis plan. Paired breast
cancer and normal mammary tissues are collected at the
Breast-Unit, IRCCS “Casa Sollievo della Sofferenza”. Upon
receipt from surgery, tissue from the bulk of the tumor, and
normal breast tissue at least 2 cm distant from cancer are
sampled by a pathologist (MC), immediately frozen in
liquid nitrogen and stored at −80°C until used. For legal
reason only one normal and one tumor specimen (approxi-
mately 50–100 mg of frozen tissue in weight) can be col-
lected from each patient. Prior written and informed
consent is obtained from each patient in accordance with
Institutional Guidelines. In order to be included in the
study, patients must be female, aged more than 18 years,
Figure 2 Diagram showing cases selection and RNA
quality evaluation.
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legal reasons. We selected among the 257 breast cancer
cases collected from January 2006 to December 2011, 150
consecutive cases with at least 36 months follow-up
(Figure 2). For each case a 5 μm eosin/ematoxylin stained
section was prepared to ensure that each tumor sample
contained more than 70% of cancer cells and to confirm
the absence of tumor cells in the normal specimen. After
this analysis, 113 samples were suitable for RNA extraction.
Additional 12 cases were excluded because RNA showed a
RNA Integrity Number (RIN) <7.0 (n = 101).
Clinicopathological data
Pathological assessment includes evaluation of histological
type, grade and stage. Estrogen Receptor (ER), Progesterone
Receptor (PgR), KI-67 labelling index and HER2 expression
were evaluated by immunohistochemistry [27,28]. The
Nottingham Prognostic Index (NPI) score was calculated
according to the following formula: NPI = 0.2xT(cm) +
N(1–3) +G(1–3), where T is the maximum diameter in cm,
N the number and the level of node metastases (1 = no
positive axillary lymph nodes; 2 = 1–3 positive axillary
lymph nodes or involvement of a node in the internal
mammary chain; 3 = more than three positive axillary
lymph nodes or involvement of both axillary and
internal mammary lymph nodes) and G the Elston and
Ellis grade. Patients are classified at low risk for NPI less
or equal to 3.4, at intermediate risk for NPI between 3.4
and 5.4, and at high risk for NPI over 5.4 [29].
RNA extraction and Reverse Transcription (RT)
According to Trizol reagent protocol (Life Technologies)
80 mg of frozen specimen were carefully and mechanically
homogenized and the mixture was transferred into a clean
1.5 ml tube using a sterile scraper. Total RNA was
extracted from samples using the TRIzol reagent accor-
ding to the manufacturer’s instructions. RNA was eluted
in RNAse free-water and stored at −80°C until used. RNA
quality was measured by using 2100 Expert Analyzer
(Agilent Technology) and only RNAs with RNA Integrity
Number (RIN) ≥7.0 were processed. RNA concentration
was quantified by the absorbance measurement at 260
and 280 nm using the NanoDropTM.1000 spectro-
photometer (NanoDrop Technologies).
Single-stranded cDNA was synthesized from 5.5 ng of
total RNA using 50 nM specific stem-loop RT primers
(miR-10b P/N 4373152 and RNU48 P/N 4373383), 1X
RT buffer, dNTPs (each at 0.25 mM), 0,25 U/μl RNase
inhibitor and 3.33 U/μl MultiScribe reverse transcript-
ase. 15 μl reactions were incubated in a GeneAmp PCR
System 9700 Thermocycler at 16°C for 30 min, 42°C for
30 min and 85°C for 5 min. RT positive and negative
controls were included in each batch of reactions. All
reagents were purchased from Life Technologies.Quantitative reverse transcription polymerase chain
reaction (RT-qPCR) analysis of miR-10b
A relative quantification method with standard curve was
developed to determine miR-10b expression in tissues
[30]. PCR fragments for the miR-10b and for RNU48 en-
dogenous control were generated using TaqMan miRNA
Parrella et al. Molecular Cancer 2014, 13:142 Page 7 of 9
http://www.molecular-cancer.com/content/13/1/142assay (miR-10b P/N 4373152 and RNU48 P/N 4373383,
Life Technologies), cloned in the StrataClone™ PCR Clon-
ing Vector pSC-A (Stratagene®) and introduced in Strata-
Clone™SoloPack® Competent Cells. Plasmid DNA from
the selected transformant cells was isolated by using the
QIAprep® Spin Miniprep Kit (Qiagen) and linearised with
Not I (Amersham) Concentration value of plasmid DNA
was measured by spectrophotometry and the plasmid
copy number was calculated using the following formula:
(X μg/μl plasmid DNA/(plasmid and insert length) ×
660 g/mole) × 6.023 × 1023 = Y molecular number/μl. X
represents the concentration of recombinant plasmid
DNA, 660 g/molecule the average MW of a double-
stranded DNA molecule and Y represents copy number.
Five plasmid dilutions of pSC-A_miR-10b and pSC-
A_RNU48 (in the range of 1 × 106 copies to 1 × 102 cop-
ies) were used to construct the five points calibration
curves for real-time PCR.
Real-time PCR reactions were performed in 384-well
plates on ABI PRISM 7900HT Sequence Detection Sys-
tem (Life Technologies). 10 μl of reaction mix contained
0.5 μl of TaqMan microRNA assay mix, 5 μl of TaqMan
Universal PCR Master Mix, No AmpErase® UNG (Life
Technologies) and 1 μl of template. PCR conditions
were as follows: at 95°C for 10 min, following by 40 cy-
cles (95°C for 15 s, 60°C for 1 min). Each plate included
the miR-10b and RNU48 calibration curves, paired nor-
mal and tumour cDNA samples from patients, positive
and negative controls of reverse transcription and multiple
water blanks; all samples were run in triplicates. The ana-
lysis was performed by using SDS 2.4 software (Life Tech-
nologie). Standard curves were constructed by plotting the
threshold cycle (Ct) values against logarithm10 of the copy
number and fitting by linear least square regression. The
level of miR-10b expression in each sample was deter-
mined as the ratio of the miR-10b copy number to the
RNU48 copy number and then multiplied by 1000 for eas-
ier tabulation ((miR-10b/RNU48) × 1000).
For each patient, Relative Expression Ratio (RER) was
determined as the ratio of miR-10b expression level in
the tumor sample to its expression level in the paired
normal tissue as previously described [31].
Efficiency of amplification was calculated for each
real-time PCR run for both miR-10b and RNU48 as fol-
lows: E = (10^(−1/slope)-1) using the slope of the stand-
ard curve plots of Ct versus log input of cDNA. The
average slope (s) of the standard curves was −3.481 ±
0.160 for miR-10b and −3.510 ± 0.172 for RNU48, indi-
cating efficiencies of 0.941 ± 0.051 and 0.927 ± 0.058, re-
spectively (Additional file 2: Figure S1a).
Assessment of precision performance of RT-qPCR
One breast cancer case showing high RER and one breast
cancer case showing low RER were used to estimate theprecision performance of RT-qPCR assay according to
the Clinical and Laboratory Standards Institute (CLSI)
recommendation. Intra-run variability was assessed by
running real-time PCR reactions in triplicate for each
paired tumor and normal sample on a 384 well plate.
Inter-run variability was assessed by repeating the assay
in five independent real-time PCR runs. Intra- and
Inter-run variability among RER values were evaluated
from the standard deviation and coefficient of variation
(CV) (Additional file 2: Figure S1b).
Immunohistochemical analysis of HOXD10 protein
Representative tumour blocks were sectioned at 3 μm
thickness. Immunohistochemical staining was performed
by the streptoavidin-biotin method. Endogenous peroxidase
in the section was blocked by incubation with 3% hydrogen
peroxide. A rabbit polyclonal antibody against the human
HOXD10 (H-80: sc-66926; Santa Cruz Biotechnology) was
used as primary antibody at a 1/100 dilution. Sections were
incubated with LSAB2 (Dakocytomation, Carpinteria, CA).
3-30-diaminobenzidine was used for colour development
and hematoxylin was used for counterstaining. Negative
controls were obtained by omitting primary antibody.
Statistical analysis
Patients’ baseline characteristics were reported as median
along with Inter Quartile Range (IQR) or frequencies and
percentages for continuous and categorical variables, re-
spectively. Time-to-event analysis was performed for pa-
tients without metastases at diagnosis by univariable and
multivariable proportional hazards Cox regression models.
Models included: miR-10b RERs, T, N, Grade, ER, PgR,
HER2 and KI67. Risks were reported as Hazard Ratios
(HR) along with their 95% Confidence Interval (CI 95%).
Overall Survival (OS) was defined as the time between the
enrollment date and cancer related death. Disease Free
Survival (DFS) was defined as the time between the enroll-
ment date and the tumor progression. Metastasis Free
Survival (MFS) was defined as the time between the en-
rollment date and the development of distant metastases.
The assumption of proportionality of the hazards was
tested by using scaled Schoenfeld residuals [32]. For the
miR-10b RERs only, HR were reported for each unitary in-
crement of 0.1 expression level (Additional file 3: Table S4).
Predicted risk probabilities were derived from the esti-
mated Cox regression models.
Models’ calibration, i.e. the agreement between ob-
served outcomes and predictions, was assessed using the
survival-based Hosmer-Lemeshow (HL) goodness-of-fit
test, a chi-squared test based on grouping observations
into deciles of predicted risk and testing associations with
observed outcomes.
Models’ discrimination, i.e. the ability to distinguish
subjects who will develop an event from those who will
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censored survival data. Comparison between C-statistics
was carried out according to Pencina and colleagues [33].
Reclassification improvement for the prediction of the
different endpoints offered by mir-10b RER over the NPI
was quantified using the survival-based net reclassifica-
tion index (NRI), following the Kaplan-Meier approach
with one-sided bootstrap-based p-values [34,35]. Since
no established risk cut-offs were available for our high
risk population, the continuous NRI (cNRI) was used.
Improvements in model discriminatory power and risk
reclassification were assessed at a time horizon of
36 months, since it is well established that the peak haz-
ard for both breast cancer recurrence and development
of distant metastases falls within 24–36 months from
surgery [36].
A p-value <0.05 was considered for statistical signifi-
cance. All analyses were performed using SAS Release
9.1.3 (SAS Institute).
Additional files
Additional file 1: Table S1. Comparison between HOXD10 expression
determined by IHC and miR10b expression in breast cancer tissues and
paired normal specimens. Table S2. Associations of clinicopathological
characteristics with miR-10b RERs in the whole patients group. Table S3.
Univariate Cox regression models evaluating the association between
clinicopathological variables and: Overall Survival (OS), Time to Progression
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